The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)

Inclusion Criteria * 1.A patient with multi-drug resistant/rifampicin-resistant pulmonary tuberculosis (MDR/RR-TB) with recent laboratory evidence (culture or molecular testing) within the last two months * 2.Age 18 years above * 3.No prior use of neither bedaquiline, delamanid, linezolid, or use for less than 4 weeks * 4.Positive culture result for mycobacterial at baseline(regardless smear positive or negative). No anti-tuberculosis treatment received within one month. * 5.For patients who don't have baseline sputum culture results,positive sputum smear and no effective anti-tuberculosis treatment administered * 6\. No history of respiratory failure or heart failure, and no clinically significant manifestations of arrhythmia, with a QTcF under 450ms * 7.Promise to adhere to the treatment and follow-up schedule, complete treatment monitoring, and promptly report adverse reactions to the responsible physician * 8.Voluntarily participate in this study and sign the informed consent form Exclusion Criteria * 1.According to DMID, peripheral neuropathy is classified as grade 3 or 4. Alternatively, participants with grade 1 or 2 neuropathy, which the investigator believes may progress/worsen during the study * 2.Elevation of ALT or AST ≥3 times the upper limit of normal, or elevation of total bilirubin and direct bilirubin ≥2 times the upper limit of normal * 3.Pregnant women or those who intent to pregnant during treatment * 4.Participants who have participated in other drug trials in the past three months * 5.Known congenital QT interval prolongation or any disease prolonging the QT interval, or QTc\>450 ms * 6.History of symptomatic arrhythmias or clinically relevant bradycardia * 7.Any cardiac disease that could precipitate arrhythmias, such as severe hypertension, left ventricular hypertrophy (including hypertrophic cardiomyopathy), or congestive heart failure with decreased left ventricular ejection fraction * 8.History of known, untreated, persistent hypothyroidism * 9.Electrolyte disturbances, especially hypokalemia, hypocalcemia, or hypomagnesemia * 10.History of allergy or known allergic reactions to any investigational drug or related substances * 11.BMI\<17 kg/m2 * 12.Karnofsky performance score under 50, or as determined by the principal investigator, the anticipated survival of the participant is not expected to exceed 6 months * 13.Participants expected to require surgical intervention following assessment of their pulmonary disease Withdrawal Criteria 1. Serious adverse events caused by the intervention 2. Confirmed QTcF interval ≥ 500ms or clinically significant ventricular arrhythmias 3. The expert panel deems the continuation of this combination regimen inappropriate 4. The patient requests withdrawal